2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
作者信息
Patsatsi Aikaterini, Kyriakou Aikaterini
机构信息
2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
出版信息
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
Abstract
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, medical professionals have been overwhelmed by questions beyond the infection itself. In dermatology practice, clinicians have been facing difficulties about the management of chronic immune-mediated skin diseases. Issues arose, such as the grade of immunosuppression or immunomodulation, discontinuation or modification of treatment, and initiation of new treatments. In this comprehensive review, we present the current evidence about the course and management of chronic inflammatory dermatoses during the COVID-19 pandemic, focusing on psoriasis, atopic dermatitis, and hidradenitis suppurativa.
摘要
自2019冠状病毒病（COVID-19）大流行开始以来，医学专业人员被感染本身之外的问题压得喘不过气来。在皮肤科实践中，临床医生在慢性免疫介导性皮肤病的管理方面一直面临困难。出现了一些问题，如免疫抑制或免疫调节的程度、治疗的中断或调整以及新治疗方法的启动。在这篇综述中，我们介绍了COVID-19大流行期间慢性炎症性皮肤病的病程和管理的当前证据，重点关注银屑病、特应性皮炎和化脓性汗腺炎。
相似文献
1
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
2
Biologic drugs during COVID-19 outbreak.2019冠状病毒病疫情期间的生物药物
Int J Dermatol. 2020 Oct;59(10):1293. doi: 10.1111/ijd.15088. Epub 2020 Aug 6.
3
Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.2019冠状病毒病大流行期间银屑病、特应性皮炎（湿疹）、化脓性汗腺炎及痤疮/玫瑰痤疮治疗指南的更新
Dermatol Online J. 2020 Oct 15;26(10):13030/qt0j5150df.
4
A Practical Guide to Using Biologics in Pediatric Dermatology.《儿科皮肤病学中生物制剂的实用指南》。
J Cutan Med Surg. 2024 Jan-Feb;28(1):59-67. doi: 10.1177/12034754231222415. Epub 2024 Jan 16.
5
[Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina].[新冠疫情对皮肤科免疫调节和免疫抑制治疗的影响：阿根廷患者及医生的态度]
Actas Dermosifiliogr (Engl Ed). 2020 Nov;111(9):806-807. doi: 10.1016/j.ad.2020.04.004. Epub 2020 Apr 29.
6
Immunobiologicals in dermatology.皮肤病学中的免疫生物制剂。
An Bras Dermatol. 2022 May-Jun;97(3):275-283. doi: 10.1016/j.abd.2021.05.016. Epub 2022 Mar 18.
7
[What's New in Dermatological Therapy?].[皮肤科治疗的新进展有哪些？]
Ann Dermatol Venereol. 2015 Dec;142 Suppl 3:S49-54. doi: 10.1016/S0151-9638(16)30006-0.
8
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.COVID-19 大流行期间化脓性汗腺炎患者的管理：免疫调节治疗的风险和获益。
Dermatol Ther. 2020 Nov;33(6):e14256. doi: 10.1111/dth.14256. Epub 2020 Sep 14.
9
No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.免疫调节治疗对SARS-CoV-2（新冠病毒病）疫苗效果无影响：对Epic Cosmos数据库中用于银屑病和化脓性汗腺炎患者的生物制剂和小分子抑制剂的横断面分析
J Am Acad Dermatol. 2024 Jul;91(1):100-102. doi: 10.1016/j.jaad.2024.03.004. Epub 2024 Mar 13.
10
Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?在新冠疫情期间，化脓性汗腺炎的生物治疗与银屑病的生物治疗有何不同？
J Dermatolog Treat. 2022 Feb;33(1):599. doi: 10.1080/09546634.2020.1771256. Epub 2020 Jun 19.
引用本文的文献
1
Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review.COVID-19大流行期间皮肤科的治疗依从性：一项综述
Cureus. 2023 Jan 24;15(1):e34141. doi: 10.7759/cureus.34141. eCollection 2023 Jan.
2
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.抗白细胞介素 23 生物制剂治疗银屑病：真实世界经验与临床试验数据对比。
Immunol Res. 2023 Jun;71(3):328-355. doi: 10.1007/s12026-022-09356-y. Epub 2023 Jan 4.
3
A cross-sectional study of dermatologists' attitudes towards COVID-19 vaccination in patients with immunobullous diseases.一项关于皮肤科医生对免疫性大疱性疾病患者接种新冠疫苗态度的横断面研究。
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e132-e134. doi: 10.1111/jdv.18674. Epub 2022 Oct 29.
4
Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol.COVID-19时代测量衰弱患者影响并改善其临床结局的方法与指标的制定。COMETA意大利方案。
Front Oncol. 2022 Jun 2;12:828660. doi: 10.3389/fonc.2022.828660. eCollection 2022.
5
The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view.新冠疫情期间COVID-19对医疗保健的总体影响：多学科视角
Health Sci Rep. 2021 Oct 1;4(4):e386. doi: 10.1002/hsr2.386. eCollection 2021 Dec.
6
Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.与 COVID-19 相关的皮肤科表现：对当前知识的全面综述。
J Med Virol. 2021 Oct;93(10):5756-5767. doi: 10.1002/jmv.27187. Epub 2021 Jul 16.
本文引用的文献
1
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.银屑病患者接受全身治疗或生物治疗不会增加患重症 COVID-19 的风险。
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e676-e679. doi: 10.1111/jdv.16761. Epub 2020 Jul 9.
2
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.在新冠疫情期间使用度普利尤单抗治疗重度特应性皮炎成年患者的管理：一项单中心真实世界经验
Dermatol Ther. 2020 Jul;33(4):e13765. doi: 10.1111/dth.13765. Epub 2020 Jun 30.
3
Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.2019年冠状病毒病疫情期间接受全身治疗的中重度化脓性汗腺炎
Dermatol Ther. 2020 Jul;33(4):e13680. doi: 10.1111/dth.13680. Epub 2020 Jun 18.
4
Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.在多伦多大学两所学术医院诊所的新冠疫情期间，患者驱动的度普利尤单抗停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):422-423. doi: 10.1177/1203475420930223. Epub 2020 May 20.
5
Comment on "Antipsoriatic treatments during COVID-19 outbreak".关于“新冠肺炎疫情期间的银屑病治疗”的评论
Dermatol Ther. 2020 Jul;33(4):e13491. doi: 10.1111/dth.13491. Epub 2020 Jun 12.
6
SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.一名接受白细胞介素-17抑制剂治疗的银屑病患者感染了新型冠状病毒。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e357-e358. doi: 10.1111/jdv.16571. Epub 2020 Jun 8.
7
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.生物制剂增加了感染 SARS-CoV-2 和住院的风险，但不会增加 ICU 收治和死亡的风险：在红色区域宣布期间来自大型队列的真实数据。
Dermatol Ther. 2020 Sep;33(5):e13475. doi: 10.1111/dth.13475. Epub 2020 May 19.
8
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.银屑病和特应性皮炎中新型冠状病毒肺炎病例的全球报告：大流行期间为医疗护理提供信息的一个契机。
Br J Dermatol. 2020 Aug;183(2):404-406. doi: 10.1111/bjd.19161. Epub 2020 Jun 10.
9
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.2019年冠状病毒病大流行对接受生物疗法治疗的慢性斑块状银屑病患者的影响：意大利北部的经验。
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
10
Reply: Potential role of Janus kinase inhibitors in COVID-19.回复：Janus激酶抑制剂在2019冠状病毒病中的潜在作用
J Am Acad Dermatol. 2020 Jul;83(1):e65. doi: 10.1016/j.jaad.2020.04.098. Epub 2020 Apr 24.
Zotero 插件